Merck is set to receive $200 million in damages from Gilead Sciences as federal jury decides on patent dispute. Merck claims they should be credited for liver therapy breakthrough.
Federal Jury Orders Gilead To Pay Merck $200 Million In Hepa C Drug Patent Dispute
Tech Times - 26 Mar 2016 03:29
Merck is set to receive $200 million in damages from Gilead Sciences as federal jury decides on patent dispute. Merck claims they should be credited for liver therapy breakthrough.
Share this Article
Recommended